The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.94

Today's change+0.06 +2.08%
Updated February 12 11:35 AM EST. Delayed by at least 15 minutes.
 

PDL BioPharma Inc

Nasdaq: PDLI
Last

(U.S.) $2.94

Today's change+0.06 +2.08%
Updated February 12 11:35 AM EST. Delayed by at least 15 minutes.

PDL BioPharma Inc up sharply

PDL BioPharma Inc is up sharply today, rallying (U.S.)$0.06 or 2.08% to (U.S.)$2.94. Over the last five days, shares have gained 0.68%, but are down 16.95% for the last year to date. Shares have underperformed the S&P 500 by 48.43% during the last year.

Key company metrics

  • Open(U.S.) $2.87
  • Previous close(U.S.) $2.88
  • High(U.S.) $2.96
  • Low(U.S.) $2.86
  • Bid / Ask(U.S.) $2.93 / (U.S.) $2.94
  • YTD % change-16.95%
  • Volume271,237
  • Average volume (10-day)2,306,181
  • Average volume (1-month)2,330,268
  • Average volume (3-month)3,306,316
  • 52-week range(U.S.) $2.58 to (U.S.) $7.43
  • Beta0.68
  • Trailing P/E1.75×
  • P/E 1 year forward1.49×
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend(U.S.) $0.20
  • Dividend yield6.80%
  • Trailing EPS(U.S.) $1.68
Updated February 12 11:35 AM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+54.26%

Based on its net profit margin of 54.26%, PDL BioPharma Inc is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX2.26%Sector:HealthcareIndustry:Biotechnology

Latest Press Releases

View more Press Releases
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2015Q2/2015Q1/2015Q4/2014
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201509/30/2015Jun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014
Revenue125138150117
Total other revenue--------
Total revenue125138150117
Gross profit--------
Total cost of revenue--------
Total operating expense87818
Selling / general / administrative87818
Research & development--------
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)0000
Other operating expenses, total--------
Operating income11613114299
Interest income (expense), net non-operating-6-7-9-9
Gain (loss) on sale of assets--------
Other--------
Income before tax11012413490
Income after tax69788455
Income tax, total41454935
Net income69788455
Total adjustments to net income--------
Net income before extra. items69788455
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items69788455
Inc. avail. to common incl. extra. items69788455
Diluted net income69788555
Dilution adjustment----10
Diluted weighted average shares164165170197
Diluted EPS excluding extraordinary itemsvalue per share0.420.470.500.28
Dividends per sharevalue per share0.150.150.150.15
Diluted normalized EPSvalue per share0.420.470.500.28